pravin dugel

Podcast Description: More than 300 clinical thought leaders, pharma industry executives, and ophthalmology investors gathered recently in San Diego, CA, for OIS XII. 

In addition to announcing pivotal new data, presenters discussed drug and device innovations, advances in clinical trials, and how to gain or maintain a competitive edge in today’s market.

For this week’s OIS Podcast, surgeon Ehsan Sadri, MD, co-founder of Visionary Ventures; and Sharon Bakalash, MD, PhD, founder and CEO of SB Strategic Development Consultants, sat down with an all-star cast of ophthalmology leaders. 

Here’s a preview of the cast and what they talk about:

·         Avellino CEO John Robson, on how he brings decades of experience analyzing data to eye care. He also explains how (and why) Avellino uses artificial intelligence and machine learning to fuel drug discovery—specifically, precision medicine therapies.

·         Dompé’s global head of medical and clinical affairs Georgea Pasedis, PharmD, gives an update on Dompé’s neurotrophic keratitis product. She also talks about how the company uses the fourth-fastest supercomputer in the world.

·         Tyler Stowater, partner and vice president of Bluestem, a private equity company based in Sioux Falls, SD, shares how the company mitigates losses in a down market, as well as his predictions for the next few months.

·         Iveric Bio president Pravin Dugel, MD, talks about Iveric’s Breakthrough Therapy designation for Zimura (avacincaptad pegol), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy.

·         Mina Sooch, cofounder and CEO of Ocuphire Pharma, gives the scoop behind Ocuphire’s exclusive license agreement with FamyGen Life Sciences and what it means for the eye care sector at large.

·         Ranya Habash, MD, cofounder of MetaMed, takes Dr. Bakalash on a tour of the metaverse.

The podcast also includes insights from Tarsier Pharma founder and CEO Daphne Haim-Langford, PhD, and Stuart Therapeutics president and CEO Eric Schlumpf.

Click “play” to listen.

Multiple reports have shown that only about 11% of Phase I clinical trials make it through to regulatory approval. Business, says retina expert Pravin Dugel, MD, president of Iveric Bio, follows a similar trajectory. Success comes only after multiple failures. 

Dr. Dugel has enjoyed success as a retina surgeon, as a principal investigator, and as president of a biopharmaceutical company focused on developing therapies for retinal disease. He became a leader in his field partly due to his fearless risk-taking and his ability to learn from the times when those risks didn’t pan out. 

An immigrant refugee from Nepal who fled to Austria with his family, Dr. Dugel followed his brother to a boarding school in England, finished high school and college in New York, and moved to the opposite coast to complete medical school, a residency, and a fellowship in southern California.

Taking a calculated risk based on what seemed like a promising market, Dr. Dugel moved to Phoenix, Arizona, to build his clinical practice, Retina Consultants of Arizona. Though it took years of trial and error, he succeeded in founding one of the most innovative retina practices in the country. He has also served as principal investigator in more than 100 clinical trials, including known products such as NeoVista and Beovu.

With host Firas Rahhal, MD, Dr. Dugel talks about what he and other investigators learned from the NeoVista clinical trials that would inform future protocols. He also discusses the science behind Zimura (avacincaptad pegol), Iveric Bio’s therapy for geographic atrophy, a part of late-stage age-related macular degeneration (AMD). 

Zimura received a special protocol assessment (SPA) from the Food and Drug Administration, which may help expedite approvals. Trial results from Zimura’s GATHER2 studies are expected in the second half of 2022.

Listen to the Podcast to find out:

• The MOA behind Zimura  and why it may have an impact on intermediate macular degeneration and wet AMD. 
• How Dr. Dugel expanded his career from traditional academic practice to research physician to biopharma entrepreneur, and the one quality that helped him along the way.
• What went wrong with NeoVista and Beovu and what the industry can learn from these studies.

Click “play” to listen.

In our latest update, We discuss clinical and business careers with Pravin Dugel MD, President, of Iveric Bio.